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                                  INTRODUCTION 
The Siddha system (Tamizh Maruthuvam) of medicine is the traditional 
medical systems in the world. The uniqueness of Siddha system is evident by its 
constant service to the humankind by the great Siddhar’s for more than 5000 years in 
combating diseases with various herbals, metals/minerals and animal products having 
several therapeutic indications.  
The Siddhar’s believes there is a divine power beyond them in achieving their 
goal and it is not been attained by searching outside. The following stanzas from 
“Kagapusundar Gnanam 80” texts written by Siddhar Kagapusundar clearly states 
that “the divine power is inside you, without knowing it why this mankind is wasting 
their time in searching for several forms of divine power.  
  The Siddha System contains unlike blend of remedy for similar ailment. 
Medicine will be handled by the Siddha physician based on Ayim bootham, Aaru 
aatharam, suvai, pragiruthi, Paalinam, three humors like Vali, Azhal, Iyam etc. This 
indicates individualism of siddha medicine purely depends on Siddha physiology to 
validate the root cause of disease by Envagai thervugal, especially Naadi-pulse 
reading method. It is good for a physician to diagnose the disease, trace its cause, how 
it may be moderated and then to use his expert skill. 
Siddha system of medicine provides the healthiness and care through 
Prophylaxis (Noyillaneri), Treatment (Maruthuvam) and Rejuvenation (Kayakarpam). 
For a physician, it nourishes knowledge about the art of diagnosis (Noi Nadal), 
pharmacology (Gunapadam) and toxicology (Nanjumurivu nool). 
Siddhars are excellent in the documentation work and they taught the above 
said sciences to their disciples too.  They wrote their works in manuscripts which is 
the spinal column for generations of Traditional healers and Siddha physicians. 
INTRODUCTION 
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 In Siddha system of medicine, Chooranam based on pure herbals is one of the 
first line of medicine for the several diseases. The shelf-life of chooranam is three 
months
1 
Siddha system of medicine is self sufficient to meet the needs of public health. 
It is high time to work on the feature assertion, safety and efficiency of Siddha 
formulations to make our system advantageous for inhabitants at large. 
The branch of Toxicology is developed by our forefathers to save the mankind. 
They discussed about the toxic effect of drugs and noxious bites with treatment to 
prevent the mortality circumstances. Siddhar’s and traditional healers have well 
knowledge about the safety aspects in therapeutic practice. 
The Aagasagarudan kizhangu is commonly called as “Kollankovai kizhangu”, 
“Garudan”, “Aagayagarudan”, “Peicheenthil”, etc. According to 
Thiru.T.V.Sambasivam pillai dictionary, the word „Aagasagarudan‟ refers to ‘root 
living in air’. It is a climbing shrub with yellow flowers2. The therapeutic uses of 
Aagasagarudan kizhangu are indicated for Virulent poison (Kodiya nanju), Anemia 
(Paandu), Pruritus (Namaichal), Thyroidism (Kazhuththu Kazhalai), Leprosy 
(Perunoi), Herpes zooster (Akkipun)
3
. 
I wished for working in the field of Siddha toxicology and was permitted to do 
the safety evaluation of ‘Aagasagarudan kizhangu Chooranam’- a Siddha herbal 
preparation which is indicated for several illness and virulent noxious bite. Snake bite 
is a life threatening problem causing mortality from ancient period to till date. About 
94,000 snake bite deaths are recorded globally and 15000 in India per year
4
. Even 
today treating the noxious cases is a dare to the medical profession, but treating such 
noxious cases through the Siddha system of medicine seems to be more abundant and 
cost effective, hence this meticulous formulation had been preferred in a broad vision.  
 
AIM AND OBJECTIVES 
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AIM AND OBJECTIVES 
AIM: 
To evaluate the safety profile of “AAGASAGARUDAN KIZHANGU 
CHOORANAM” – A herbal preparation 
OBJECTIVES: 
 Aagasagarudan Kizhangu authenticated by Botanist. 
 To do the following studies on Aagasagarudan Kizhangu 
Chooranam. 
 Physicochemical analysis 
 Biochemical analysis 
 Heavy metal analysis using ICP-OES 
 Phytocompound analysis using GC-MS 
 Organic Functional group analysis using FT-IR 
 Acute Oral Toxicity study as per WHO guideline 
 Long term Oral Toxicity study as per WHO guideline 
 
REVIEW OF LITERATURE 
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CORALLOCARPUS EPIGAEUS 
A genus of climbing and trailing herbs, distributed in the tropical Asia, Africa 
and Malagasy. About five species occur in India.  
HABITAT:  
A perennial climber, found in dry, arid areas throughout India. Roots conical 
or napiform, yellowish white, marked externally with circular rings; stems slender, 
grooved with simple, glabrous tendrils; leaves variable in shape and size, usually 2 – 
10 cm long, pubescent, 3 – 5 lobed, long petioled; male flowers 4 – 15, in clusters, 
yellowish green; female flowers solitary or fasciculated on glabrous peduncles; fruits 
scarlet except in beak and base, ellipsoid or ovoid, beaked, 12 – 16 cm x 7 – 8 mm; 
seeds 6 – 9, ellipsoid or pyriform, brown or yellow, embedded in orange pulp. 
The root has a bitter and sub-acidic taste and is mucilaginous. When cut, it 
exudes a viscid juice which soon hardens into an opalescent gum. It contains bitter 
principles cucurbitacin B and another allied to bryonin. The root is credited with 
aperients, alternative and emetic properties; a paste of it is applied o swelling.
8
 A 
liniment made from it along with cumin seeds, onion and castor oil is applied in 
chronic rheumatism. The fruit is a drastic purgative and emetic 
9
.  
Flowers and fruiting on June to October 
10
. The root contains phydroxybenzoyl 
ester, named epigaeusyl ester, a sesterpene lactone, viz. corallocarpscalaride, a 
pyridine carboxylic ester, designated as corallocarpeonyl ester 
11
. Deccan and Mysore 
REVIEW OF LITERATURE 
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the root has repute as a remedy for snakebite administered internally and applied to 
bitten part 
12
. 
Parts Used       :  Whole plant and Rhizome.  
Odour              :   Pungent 
Taste                :   Bitter.  
Indications      :  
It was used for many inflammatory diseases. 
Effective in Asthma, Bronchitis. 
13 
SYNONYMS: 
 BRYONIA EPIGAEA 
Common name : Redfruit creeper
14 
Tamil   : Akasagerudan kizangu, Kollankovai 
Malayalam  : Kollankova, Kollanhova-kizhauna, Nagadonda 
Telugu  : Akashagadda, Makkasagaddah, Nagadondagadda 
Kannada  : Akashagaruda-gaddah 
Bengali  : Rakasgaddah 
Gujarathi  : Kadavinai 
Hindi   : Akasgaddah, Rakasgaddah 
Marathi  : Akashgarudand, Kadavinai 
Madhya Pradesh : Keerkand, Mirchakand 
Rajasthan  : Kadawi-nai, Mirchi-kand
8 
Sanskrit  : Kadamba
14 
 
REVIEW OF LITERATURE 
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                                  Fig: 1. AAGASAGARUDA KIZHANGU PLANT 
  
              
Fig: 2. AAGASAGARUDA KIZHANGU
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TAXONOMICAL CLASSIFICATION
15
: 
Kingdom : Plantae 
Clade  : Angiosperms 
Clade  : Eudicots 
Clade  : Rosids 
Order  : Cucurbitales 
Family  : Cucurbitaceae 
Subfamily : Cucurbitoideae 
Tribe  : Coniandreae 
Genus  : Corallocarpus 
Species : Epigaeus  
Table 1: Types of Species in Genus Corallocarpus
16
:  
Types of Species Native 
Corallocarpus epigaeus India, Oman, Africa 
Corallocarpus bainesii Africa 
Corallocarpus boehmii    Africa 
Corallocarpus Welwitschii Africa 
Corallocarpus triangularis Africa 
 
                   In many developing countries, Traditional medicine plays an important 
role in meeting the primary health care needs of the population. Some studies have 
shown that individuals choose Traditional medicine for various reasons, including an 
increasing dissatisfaction with existing health-care services, and a rekindled interest in 
REVIEW OF LITERATURE 
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„whole person care‟ and disease prevention which are more often advocated in 
Traditional medicine
17 
In Gunapadam (Mooligaivaguppu) text book, Aagasagarudan kizhangu 
(Corallocarpus Epigaeus) Chooranam is mentioned for Namaichal, which is the 
primary sign in the Kaanaakkadi. Several scientific researches on tuber of 
Aagasagarudan kizhangu reported to possess Anti-snake venom, anti-diabetic, anti-
fungal, anti-steroidogenic, anthelmintic, anti-inflammatory, analgesic, spasmolytic 
activities
18
 . 
NUTRITIONAL VALUES: 19 
The Nutritive elements per 100 grams of methanolic extracts of tuber contain 
Carbohydrates    -    46.43 mg 
Protein                -     21.17mg 
Fat                      -     2mg 
Crude fibres       -     5 mg, 
Calcium             -     0.225 mg, 
Magnesium        -     0.124 mg, 
Phosphorus        -     0.049 mg, 
Iron                    -     0.006 mg 
Vitamin C         -     0.051 mg 
Calories            -     288.4mg   
CHOORANAM: 
Definition: Chooranam are fine dry powders of drugs. The term chooranam 
may be applied to the powders of single drug or a mixture of two or more drugs which 
are powdered separately prior to their being mixed to homogeneity. 
Shelf life of Medicines: 
 The shelf life of medicines indicates the Potency of medicines. Siddha 
medicines can be classified into internal and external medicines. Chooranam comes 
REVIEW OF LITERATURE 
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under internal medicines. As per Siddha literature Agamarunthu paadal in Gunapadam 
thathu jeevam text, 
 
From the above quote the shelf life of chooranam (powder) is three months, 
but according to AYUSH guidelines the shelf life of chooranam is one year
 20
 
RESEARCH ARTICLES PUBLISHED IN JOURNALS: 
Anti-allergic Activity 
Kollankovai kizhangu is one of the ingredient in drug G7 (manufactured and 
marketed by  Dr. JRK Siddha Research and Pharmaceuticals Pvt. Ltd., Chennai, India) 
which is effective in preventing histamine release from mast cells, reported to have 
anti allergic activity
21 
 
Anti-diabetic Activity 
 
The alpha amylase inhibition assay by DNS method revealed that the methanol extract 
showed inhibition of α-amylase enzyme activity at low concentration. The presence bioactive 
compound conferring the amylase inhibition in the methanol extract of tuber could possibly 
contribute to the anti-diabetic activity
22,23
 
 
Haemopoietic Activity 
According to this clinical study, Corallocarpus epigaeus rhizome Choornam on 
Pandu Rogam with special reference to iron deficiency anemia showed moderately 
significant result in improving hemoglobin concentration and significant result in the 
relieving of symptoms like Exertional tiredness, Palpitation, Paleness and 
Tachycardia. Effectiveness of drug is discussed on the basis of suvai, Veeriya, Vipaka, 
action and properties of selected plant
24 
Anti-cancer Activity 
This current study is a preliminary effort to evaluate cytotoxic potential of 
whole plant ethanolic extract of Corallocarpus epigaeus against K562 cell lines 
REVIEW OF LITERATURE 
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employing Trypan blue and MTT In-vitro cytotoxic assay. The study revealed a dose 
dependent reduction in number of K562 cell lines upon single exposure for 48hrs 
which indicates that the extract may be capable of altering the membrane permeability 
and functioning of mitochondrial dehydrogenase synthase. Further studies were 
implicated to identify individual phyto-constituents responsible for cytotoxicity and 
elucidation of probable mechanism of action may lead to the development of 
promising natural agents in the treatment of Chronic Myeloid leukaemia
25 
 
Antimicrobial Potency 
This study revealed that the medicinal plant Corallocarpus epigaeus has the 
capability of Antifungal as well as antibacterial activity. The phytochemical analysis 
revealed that the phytochemicals present in the tuber contributes to antimicrobial 
activity
26 
Antioxidant and anti-inflammatory Activities 
This study, the different extract of Corallocarpus epigaeus rhizomes was found 
in valuable levels total free phenol, tannins and flavonoid which is promising 
antioxidant activity. The extract of Corallocarpus epigaeus rhizomes exhibits potential 
anti-inflammatory effect. The extract is almost compared with the standard 
indomethacin. The present study supports the traditional medicine system, of the 
rhizome for their use in antioxidant and anti-inflammation
27 
Invitro Cytotoxic Activity 
This study, the root extract of Corallocarpus epigaeus showed cytotoxic 
activity against HT-29 and MCF-7 cell lines with the percentage mortality increased 
with an increase in concentration
28 
 
Antidote Activity 
Field survey undertaken in 12 mandal areas out of 62 mandals of Chittoor 
district revealed the occurence of 31 medicinal plants especially used as antidote ones 
against snake-bite. The possible number of tribal doctors that prefer the individual 
plant species for treating snake-bite. Of all the plants 3 plant species like 
REVIEW OF LITERATURE 
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Aganosmacymosa, Corallocarpus epigaeus and Randiadumetorum were found to be 
preferred by more than 70% of tribal doctors to treat snake-bites
29
 
Chemical and Biological properties 
Bryonia epigaea (Rottler) is the most instinctive plant having wide range of 
activities. Wide ranges of compounds were analyzed in methanolic extract. The 
antimicrobial efficiency of Bryonia epigaea (Rottler) aerial part extracts showed good 
results against various pathogens Methanol extract showed good anti-oxidant activity. 
Bryonia epigaea (Rottler) aerial parts were analyzed for its biological activities and 
further isolation and charecterization of the compounds with biological activities will 
certainly add a valuable invention in the field of drug discovery
30 
Anti-Snake Venom Activity 
Invivo antisnake venom studies of the methanolic extract of Corallocarpus 
epigaeus reveals significant antisnake venom activity and could have a promising role 
in the treatment of Russell‟s viper snake bite.  The exact mechanism of antisnake 
venom and isolation of active constituents has to be evaluated
31 
Antidiabetic Activity 
This study, it can be concluded that the ethanolic extract of Corallocarpus 
epigaeus rhizomes possesses the antidiabetic action which is comparable with that of 
the standard Glibenclamide drug employed. This work supports the traditional claim 
of the rhizomes for their use in diabetes
32 
Anthelmintic Activity 
The anthelmintic activity was evaluated on adult Indian earthworms Lampito 
marutii, Eudrillus eugine, Eisenla foetida due to its anatomical and physiological 
resemblance with the intestinal roundworm parasites of human being and also in 
intestinal roundworms. The method of Mathew et al was followed for anthelmintic 
screening
33,34,35,36
 
 
Antifungal Activity 
The antifungal activity of petroleum ether, hexane, chloroform, acetone and 
methanol extracts obtained from Corallocarpus epigaeus revealed that only the 
methanol extract showed a good antifungal activity against the fungal strains
37 
REVIEW OF LITERATURE 
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Anti-inflammatory and analgesic Activities 
 Kollankovai kizhangu is one of the ingredients in the sasthric Siddha herbo-
mineral drug Gendhaga Vallaathi which is effective in rheumatoid arthritis. The 
ingredients of this drug possess various activities such as Anti-inflammatory, 
analgesic, antipyretic, antioxidant and immunomodulatory activity
38 
 
IMPORTANCE OF SUDDHI IN SIDDHA SYSTEM OF MEDICINE 
The word “Suddhi” means “to get rid of impurities”39. The concept of Suddhi 
(Purification) in Siddha text is not only a process of Purification/detoxification. It also 
enhances the potency and efficacy of the drug. Researches in various Herbal, Mineral 
and Metal purification process reveals the following changes occur, 
1. Elimination of physical impurities 
2. Organoleptic changes 
3. Changes the hardness of a drug 
4. Reduction in particle size 
5. Reduction of toxic substance 
6. Changes in chemical structure 
7. Changes in Elements 
8. Changes in the Pharmacological action  
 
Recent Researches in various purification process 
1. Elimination of physical impurities 
 By purification process the physical impurities of the drug like, sand particle, 
mud, insect, foreign particles get removed. 
2. Organoleptic changes 
  Raw Croton was Blackish in colour, it was changed to Brown in purified one40 
  The colour of sulphur before purification was bright yellow and shiny in 
nature, it was changed to yellow colour in after purification. 
 The smell of sulphur in before purification is pungent in nature, after it was 
turned to odourless
41
. 
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4. MATERIALS AND METHODS 
COLLECTION: 
The Aagasagarudan kizhangu were collected from a reputed raw drug shop at 
Broadway Chennai. 
AUTHENTICATION:  
The Herbal drug Aagasagarudan kizhangu is identified and authenticated by 
Assistant Professor, Department of Medicinal Botany, National Institute of Siddha, 
Chennai-47. 
 
PREPARATION OF TEST DRUG: 
SELECION OF TEST DRUG: 
The test drug Aagasagarudan kizhangu was selected for the evaluation of 
toxicity studies in Wister albino rats. 
INGREDIENTS: 
 Aagasagarudan kizhangu (Corallocarpus epigaeus) –  1 part 
 Naattu sarkkarai                           –  equal part 
METHOD OF PURIFICATION AND PREPARATION: 
Decayed parts or the mud sticking to the Aagasagarudan kizhangu are removed 
and then the skin of tuber was peeled. The skinless tuber was sliced and dried in 
sunshade. Then it was grounded well to obtain fine powder and purified through 
‘pittavial process. After this process, the dried powder was sieved through white cloth 
and it was mixed with equal quantity of Naattu sarkkarai and stored in an air tight 
container and it was labelled as Aagasagarudan Kizhangu Chooranam. 
Pittaviyal Murai (Milk steaming process): 
             The Aagasagarudan Kizhangu Chooranam was purified by Pittaviyal process 
as per Siddha classical literature. A mud pot was taken and it was quarter filled by 
MATERIALS AND METHODS 
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water. The mouth of the pot was sealed by cloth. This Chooranam was then placed 
over the cloth and the pot was covered with lid and heated. After this process the 
powder was dried, sieved, mixed with sieved Naatu sarkkarai and stored in an air tight 
container 42. 
THERAPEUTIC DETAILS OF AAGASAGARUDAN KIZHANGU 
CHOORANAM: 
Form of the Medicine      :   Chooranam (Powder) 
Route of Administration  :   Enteral 
Clinical dose       :   Half to One Varaagan (2-4 grams) 
Adjuvant        :   Naattu sarkkarai      
  
Indication                         :   Virulent poison (Kodiya nanju)  
          Anemia (Paandu)  
          Pruritus (Namaichal)  
          Thyroidism (Kazhuththu Kazhalai)  
           Leprosy (Perunoi)  
          Herpes zooster (Akkipun) 
MATERIALS AND METHODS 
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      Fig A            Fig B                                                 Fig C 
 
  
                      Fig D                                            Fig E                             
              
       
Fig A. Raw Aagasagarudan kizhangu  
Fig B. Skinless Aagasagarudan kizhangu  
Fig C. Unpurified Aagasagarudan kizhangu chooranam 
Fig D. Aagasagarudan kizhangu chooranam under  purification process  
Fig E. Purified Aagasagarudan kizhangu chooranam  
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4.2. QUALITATIVE ANALYSIS  
4.2.1 PHYSICO CHEMICAL ANALYSIS 
      The Aagasagarudan kizhangu chooranam was studied by physicochemical 
parameters. This study was done at The Tamil Nadu Dr.M.G.R. Medical University 
No.69, Annasalai, Guindy, Chennai-600032. 
1. Loss on drying of the sample at 105ºC 
4g of test drug was weighed in a previously weighed 100ml beaker and heated 
in an oven at 105ºC for 5hours. Cooled in a dessicator and weighed.  Repeated the 
procedure till constant weight was obtained.  The percentage loss in weight of the test 
drug was calculated by the following formula. 
     Calculation: 
                                                                       Loss in weight of test drug   
     Percentage of loss on drying at 105ºC =  ----------------------------------------- x 100 
                                                                        Weight of test drug taken  
 
2. Ash content  
a. Total ash content  
4g of test drug was weighed accurately in a previously ignited and tarred silica 
dish.  The material was evenly spread and ignited in a muffle furnace at 600⁰C until it 
became white indicating the absence of carbon.  The dish was cooled in a dessicator 
and weighed.   As carbon free ash cannot be obtained in this manner, the dish was 
cooled and the residue moistened with sufficient quantity of water.  Dried on a water 
bath and then ignited in the electric furnace to get the constant weight. Cooled the dish 
in a dessicator and then weighed. The percentage of total ash of air-dried materials 
was calculated as per the formula given below.  
              Calculation: 
                                             Weight of the ash 
          Percentage of total ash  =  ----------------------------------- x 100 
                                                   Weight of test drug taken 
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b. Acid-insoluble ash  
             The total ash of the test drug was found out as described above. To the dish 
containing the total ash was added 45 ml of 1: 5 hydrochloric acid in three portions of 
13 ml each time.   
Boiled gently for 5 minutes and filtered. Collected the insoluble matter on an 
ashless filter paper (Whatman No.41) and washed with distilled water until the residue 
was free from acid.  Transferred the filter paper containing the insoluble mater to the 
original dish.  Dried and ignited to the constant weight. Cooled the dish in a 
dessicator, and then weighed.  Calculated the percentage of acid-insoluble of the air-
dried material by the given following formula43  
 
       Calculation:                                             
                                                                     Weight of the acid-insoluble residue   
        Percentage of acid-insoluble ash   =   -------------------------------------------- x 100 
                                                                          Weight of test drug taken 
 
i. Extractive of the test drug  
 
a. Water-soluble extractive of the test drug  
       4 g of the test drug was weighed accurately in a glass stoppered flask. Add 100 ml 
of distilled water and shakened occasionally for 6 hours and then allowed to stand for 
18 hours. Filtered rapidly taking care not to lose any solvent and pipetted out 25 ml of 
the filtrate in a preweighed 100 ml beaker and evaporated to dryness on a water bath. 
Kept in an air oven at 105ºC for 6 hours.  Cooled in a dessicator and weighed.  
Repeated the experiment twice, and taken the average value. The percentage of water 
soluble extractive was calculated by the formula given below. 
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   Calculation: 
                                                                 Weight of the extract            100 
     Percentage of water soluble extract = --------------------------------  x  -------- x 100 
                                                                    Weight of sample taken           25 
 
b. Alcohol-soluble extractive of the sample   
       4 g of the sample was weighed accurately in a glass stoppered flask. Added 100 
ml of distilled alcohol (approximately 95%) and shaken occasionally for 6 hours and 
then allowed to stand for 18 hours.  Filtered rapidly taking care not to lose any solvent 
and pipetted out 25 ml of the filtrate in a pre-weighed 100 ml beaker and evaporated 
to dryness on a water bath.  
Kept in an air oven at 105ºC for 6 hours and cooled in a dessicator and 
weighed.  Repeated the experiment twice, and taken the average value. The percentage 
of alcohol soluble extractive was calculated by the formula given below. 
Calculation: 
   
                                                                   Weight of the extract          100 
Percentage of alcohol soluble extract = ----------------------------------- x --------- x 100  
                                                                     Weight of sample taken           25 
 
 
ii. Determination of pH 
The pH of the Aagasagarudan kizhangu was estimated as per the method 
prescribed in the Indian standard (IS) - 6940(1982).  
 One gram of the test drug was taken into a 100ml graduated cylinder 
containing about 50 ml of water. The cylinder was  shaken vigorously for two minutes 
and the suspension was allowed to settle for hour at 25ºC  to 27ºC, then 25 ml of the 
clear aqueous solution was transferred in to a 50 ml beaker and tested for pH using 
digital pH meter. 
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4.2.2 BIO-CHEMICAL ANALYSIS: 
The bio-chemical analysis of Aagasagarudan kizhangu was done at 
Biochemistry lab, National Institute of Siddha, Chennai-47. 
Table 4.2.2 Experimental procedures of Chemical analysis 
 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.  Appearance of sample Pale brown in 
colour 
 
2. 
 
Test for Solubility: 
a. A little (500mg) of the sample is 
shaken well with distilled water. 
b. A little (500mg) of the sample is 
shaken well with con. HCl/Con. 
H2So4 
                     
Sparingly soluble 
 
Completely soluble 
 
Presence  of 
Silicate 
 
Absence of 
Silicate 
3. Action of Heat: 
   A small amount (500mg) of the 
sample is taken in a dry test tube 
and heated gently at first and then 
strong. 
White fumes    
evolved 
 
Presence of 
Carbonate 
 
4. Flame Test: 
  A small amount (500mg) of the 
sample is made into a paste with 
Con.HCl in a watch glass and 
introduced into non-luminous part 
of the Bunsen flame. 
 Bluish green flame 
not appeared. 
Absence  of 
Copper 
5. Ash Test: A filter paper is soaked 
into a mixture of sample and dil. 
cobalt nitrate solution and 
introduced into the Bunsen flame 
and ignited 
No yellow colour 
flame appeared 
Absence of 
sodium 
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Preparation of Extract:  
       5gm of Aagasagarudan kizhangu is weighed accurately and placed in a 250ml 
clean beaker and 50ml of distilled water was added with it. Then it was boiled well for 
about 10 minutes. Then it was allowed to cool and filtered in a 100ml volumetric flask 
and made up to 100ml with distilled water44 
Table4.2.3 Experimental procedures of Biochemical analysis 
S.No EXPERIMENT OBSERVATION INFERENCE 
 
I. Test For Acid Radicals 
1. Test For Sulphate: 
2ml of the above prepared extract was 
taken in a test tube and 2ml of 4% dil. 
ammonium oxalate solution was added. 
No Cloudy 
appearance 
 
Absence of 
Sulphate  
2. Test For Chloride:  
 2ml of the above prepared extracts was 
added with 2ml of dil-HNO3 until the 
effervescence ceases off. Then 2 ml of 
silver nitrate solution was added. 
No Cloudy 
appearance 
Absence of 
Chloride 
 
3. Test For Phosphate: 
 2ml of the extract was treated with 2ml 
of con.HNo3 and 2ml of dil.ammonium 
molybdate solution.  
 
No Yellow 
precipitate 
 
Absence of 
Phosphate 
4.  Test For Carbonate: 
2ml of the extract was treated with 2ml 
dil. magnesium sulphate solution 
Cloudy 
appearance 
present 
 Presence of 
Carbonate 
5. Test For Nitrate: 
1ml of the substance was heated with 
copper turning and concentrated H2SO4 
and viewed the test tube vertically down. 
Brown gas was 
not evolved 
Absence of 
Nitrate 
6. Test For Sulphide: 
1ml of the substance was treated with 
2ml of con. HCL 
No Rotten Egg 
Smelling gas 
was evolved 
Absence of 
Sulphide 
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7. Test For Fluoride & Oxalate: 
  2ml of extract was added with 2ml of 
dil. Acetic acid and 2ml dil.calcium 
chloride solution and heated. 
 
No Cloudy 
appearance 
Absence of 
fluoride and 
oxalate  
8. Test For Nitrite: 
3drops of the extract was placed on a 
filter paper, on that-2 drops of dil.acetic 
acid and 2 drops of dil.Benzidine solution 
were placed. 
 
 
Characteristic 
changes not 
appeared 
Nitrite absent 
 
II. Test  For Basic Radicals 
1. Test For Lead: 
2ml of the extract was added with 2ml of 
dil.potassium iodine solution. 
 
No Yellow 
Precipitate is 
obtained. 
 
Absence of 
Lead          
2. Test For Copper: 
One pinch (50mg) of substance was made 
into paste with con. HCl in a watch glass 
and introduced into the non-luminuous part 
of the flame. 
No Blue colour 
precipitate 
formed. 
 
Absence of 
Copper                        
 
3. Test For Aluminium: 
  To the 2ml of extract dil.sodium 
hydroxide was added in 5 drops to excess. 
No 
characteristic 
changes 
Absence of 
Aluminium  
4. Test For Iron: 
a.To the 2ml of extract add 2ml of 
ammonium thiocyanate solution. 
b.To the 2ml of extract 2ml  ammonium  
thiocyanate solution and 2ml  of con HN03 
is added 
Presence of mild 
red color 
appearance 
Presence of mild 
Red colour was 
formed 
Presence of 
Iron   
 
Presence of 
Iron 
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5. Test For Zinc:  
 To the 2ml of the extract dil.sodium 
hydroxide solution was added in 5 drops to 
excess and dil.ammonium chloride was 
added.  
No White 
precipitate 
formed 
Absence of 
Zinc           
6. Test For Calcium:  
2ml of the extract was added with 2ml of 
4% dil.ammonium oxalate solution  
 
Cloudy 
appearance was  
formed 
Presence of 
Calcium   
7. Test For Magnesium:  
2ml of the extract dil.sodium hydroxide 
solution was added in drops to excess. 
 
white precipitate 
not formed 
 
Magnesium 
absent 
8. Test For Ammonium: 
To 2ml of the extract 1 ml of Nessler's 
reagent and excess of dil.sodium hydroxide 
solution were added. 
 
Brown colour 
formed 
  Presence of    
Ammonium  
9. Test For Potassium: 
 A pinch (25mg) of substance was treated 
with 2ml of dil.sodium nitrite solution and 
then treated with 2ml of dil.cobalt nitrate 
in 30% dil.glacial acetic acid. 
 
Mild Yellowish 
red precipitate 
formed 
 
Presence of 
Potassium 
10. Test For Sodium: 
2 pinches (50mg) of the substance was 
made into paste by using HCl and 
introduced into the blue flame of Bunsen 
burner. 
 
Yellow colour 
flame not 
appeared 
 
Sodium      
absent 
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III. Other constituents 
1.  Test For Starch : 
  2ml of the extract was treated with weak 
dil.iodine solution  
 
Blue colour 
developed 
 
Presence of 
Starch          
2.  Test For Reducing Sugar: 
    5ml of Benedict's qualitative solution was 
taken in a test tube and allowed to boil for 2 
minutes and added 8 to 10 drops of the 
extract and again boil it for 2 minutes.  
 
The was no 
specific 
change in 
colour 
 
Absence of 
Reducing 
sugar 
3.  Test For The Alkaloids: 
a) 2ml of the extract is treated with 2ml 
of dil.potassium lodide solution.     
 
b) 2ml of the extract is treated with 2ml 
of dil.picric acid. 
 
Reddish brown 
precipitation 
formed 
Yellow 
precipitation 
formed 
 
Presence of 
Alkaloid 
 
Presence of 
Alkaloid 
 
11. Test For Mercury:  
 2ml of the extract was treated with 2ml of 
dil.sodium hydroxide solution.  
 
Yellow 
precipitate not 
formed 
 
Mercury   
absent 
12. Test For Arsenic:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution. 
 
Brownish red 
precipitate not 
formed 
 
Arsenic     
absent 
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4.  Test For Tannic Acid:  
2ml of extract was treated with 2ml of 
dil.ferric chloride solution 
 
No Black 
precipitate 
obtained 
 
Tannic acid 
absent 
5.  Test For Unsaturated Compound: 
To the 2ml of extract 2ml of dil.Potassium 
permanganate solution was added.  
Potassium 
permanganate 
was not 
decolourised 
 
 
unsaturated 
compounds 
absent 
6.  Test For Amino Acid: 
2 drops of the extract was placed on a filter 
paper and dried well, then 20ml of Biurette 
reagent was added in it. 
 
Violet colour 
not  developed 
 
Amino acids 
absent 
7. Test For phenols: 
2ml of the extract was treated with 2 ml of 
dil.ferric chloride solution.  
 
No specific 
colour 
formation 
 
Phenols    
absent 
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4.3. QUANTITATIVE ANALYSIS 
4.3.1 HEAVY METAL ANALYSIS 
 The analysis of heavy metals and trace elements were estimated by using 
Inductively Coupled Plasma Optical Emission Spectrometry (ICP- OES). The 
Experimental Procedure was done at SAIF, IIT Madras, Chennai-32. 
 
ICP-OES: 
 Perkin Elmer Optima 5300DV was used for standard ICP-OES analysis. The 
optimized operating conditions are given in (table 5), the wave length of analytical 
lines is given in table (5) and the test drug Aagasagarudan kizhangu underwent 
microwave digestion for sample preparation. With respect to other kind of analysis 
where chemical speciation was relevant. Only total essential concentration was 
analyzed by ICP-OES. 45 
 
Table 4.3.1: ICP- OES Operating Conditions 
Rf frequency 40 M Hz  
Range 165 – 782 nm 
Detection limit Up to ppm level using SCD detector 
 
4.3.2 ANALYSIS OF PHYTOCOMPOUNDS 
The analysis of Phytocompounds is performed by using Gas chromatogram 
Mass spectroscopy (GC-MS). The Experimental Procedure was done at SAIF, IIT 
Madras, Chennai-32. 
 
MATERIALS AND METHODS 
 
PRECLINICAL SAFETY EVALUATION OF AAGASAGARUDAN KIZHANGU CHOORANAM      29 
 
 
GC-MS ANALYSIS: 
GC-MS analysis of the methanol extract of Aagasagarudan kizhangu 
chooranam was performed using a Agilant GC system comprising an AOC-20i auto-
sampler and a Gas Chromatograph interfaced to a Mass Spectrometer (GC-MS) 
equipped with a Elite-5MS (5% diphenyl/95% dimethyl poly siloxane) fused a 
capillary column (30 × 0.25 μm ID × 0.25 μm df). For GC-MS detection, an electron 
ionization system was operated in electron impact mode with ionization energy of 70 
eV. Helium gas (99.999%) was used as a carrier gas at a constant flow rate of 1 
ml/min, and an injection volume of 2 μl was employed (a split ratio of 10:1). 
The injector temperature was maintained at 250 °C, the ion-source temperature 
was 200 °C, the oven temperature was programmed from 110 °C (isothermal for 2 
min), with an increase of 10 °C/min to 200°C, then 5 °C/min to 280°C, ending with a 
9 min isothermal at 280 °C. Mass spectra were taken at 70 eV; a scan interval of 0.5 s 
and fragments from 45 to 450 Da. The solvent delay was 0 to 2 min, and the total GC-
MS running time was 36 min. The relative percentage amount of each component was 
calculated by comparing its average peak area to the total areas. . The mass-
spectrometer used in this analysis was JEOL GC-MATE-II, and the software adopted 
to handle mass spectra and chromatograms was a JEOL Ver.2.0 and NIST library 
Ver.2.0 was used. 
4.3.3 ANALYSIS OF ORGANIC FUNCTIONAL GROUPS - FTIR 
 The analysis of some organic functional groups was determined using FT-IR 
Spectra.  The Experimental Procedure was done at SAIF, IIT Madras, Chennai-32. 
          The Perkine Elmer Spectrum One Fourier Transform Infrared (FTIR) 
Spectrometer was used to derive the FT IR Spectra of Aagasagarudan kizhangu 
chooranam in Potassium Bromide (KBr) matrix with scan rate of 5 scan per minute at 
the resolution 4cm-1 in the wave number region 450-4000cm-1. The samples were 
grounded to fine powder using agate motor and pestle and the mixed with KBr46  
            They were then Pelletized by applying pressure to prepare the specimen (the 
size of specimen about 13 mm diameter and 0.3 mm in thickness) to recorded the FT- 
IR Spectra under Standard conditions.  
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 FT-IR is an important and advanced technique to identify the functional group 
to determine the quality and consistency of the sample material. And can determine 
the amount of compounds in the sample. It was an excellent for quantitative analysis.47 
The spectrum that appears denotes the molecular absorption and transmission. 
The peaks seen in the spectrum indicates the amount of materials present in it.48 
 
4.4 TOXICITY STUDIES OF AAGASAGARUDAN KIZHANGU 
CHOORANAM 
To evaluate the safety profile of Aagasagarudan kizhangu chooranam with 
acute and sub chronic toxicity study carried out as followed 
 Principles of laboratory animal care were followed and the Institutional 
Animal Ethical Committee approved the use of animals and the study design. 
Institutional Animal Ethical Committee number: (IAEC). (NIS/IAEC-II/11/2016) 
dated 29.9.2016. 
1. ACUTE TOXICITY STUDY OF AAGASAGARUDAN KIZHANGU 
CHOORANAM 
            Species               : Wister albino Rats 
 Sex      : Male and Female  
 Age/weight at start of test  : 6 weeks/140-160g b.wt 
 Acclimatization Period  : 7 days prior to dosing 
 Housing    : Polypropylene cages 
 Husbandry    : 12-h light/12-h dark artificial  
        photoperiod/ Room temperature 
       22°C (±3°) and relative humidity 
       30–70% 
 Feed and Water   :  Rodent pelleted feed   
                             RO purified water ad libitum 
         Identification    : Animals will be kept in individual 
        cages and numbered 
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Experimentation Details of Acute toxicity study: 
            Groups/treatment regimen  : Grouped by randomisation 
 Test guideline   : WHO 
 Length of exposure to  
 test substance   :           Single dose 
 No of animals  : 5Male + 5 Female/group 
            Control group   : Vehicle 
Test groups                             :            Aagasagarudan kizhangu chooranam 
(Low, Mid, High dose) 
 Healthy Wister Albino rats of both sexes weighing 150-200g were obtained 
from authorized animal breeders of the animal laboratory in TANUVAS, 
Madhavaram, and Chennai and stocked in the animal house at National Institute of 
Siddha, Chennai. Animals were housed in a cage at 25°C and have free access to 
standard rat pellet diet. The animals were administered with Aagasagarudan kizhangu 
chooranam by oral route for one day and monitored for behavioral parameters for the 
first 4 hours after drug administration. Body weight of the animal will be monitored at 
weekly intervals. The animals that die within this period will be subjected to necropsy.  
Remaining animals will be weighed and sacrificed under the injection of Pentothal 
sodium after 14 days of drug administration. The toxicological effect was assessed on 
the basis of mortality and behavioral parameters. 
Preparation of Test Drug Doses: 
 
                                                                                Total 20(10M+10F) 
 
 
 
Groups No. of Rat 
Group I:  Vehicle control (Water) 10(5M+5 F) 
GroupII: Test drug (Aagasagarudan kizhangu 
chooranam) – 2000mg/kg b.wt 
10(5M+5F)  
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Route of administration: 
 Oral route was selected because it is the normal route of clinical 
administration. 
 
Administration of Dose: 
 The animals were fasted (only food was with held) for 12hrs and weighed prior 
to dosing. Three animals were used for each step. A single dose of the test drug 
(2000mg/kg.b.wt) was consecutively administered by oral gavage using intubation 
cannula. The food was withheld for another 4hrs after dosing and administration of the 
drug.  
 
Observations 
Observation were made and recorded systematically and continuously observed 
after the substance administration as per the guidelines. 
 Mortality, behavioural changes  
 ½ hour , 1 hour, 2 hour ,4 hour and upto 24 hours observation 
 All rats were observed twice daily for 14 days 
 Body weight was observed once in a week. 
 Feed intake was calculated daily. 
 Water intake was calculated daily. 
 
a. Cage-side observation  
 Clinical observation includes Mortality, convulsion, tremor, sedation, excitation, 
abnormal gait, motor coordination, piloerection, head movements, reactivity to touch, 
gripping, grooming, exophthalmos, diarrhoea, salivation, lacrimation, posture, 
dyspnoea and coma. 
b. Gross necropsy 
At the end of the 14thday, all the animals were sacrificed by using the injection 
of Pentothal sodium Gross necropsy includes examination of the external surface of 
the body, all orifices, cranial, thoracic and abdominal cavities and their contents like 
brain, lung, heart, spleen, liver, kidney, uterus, testes, ovary of all animals.  
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2. LONG TERM TOXICITY STUDY OF AAGASAGARUDANKIZHANGU 
CHOORANAM 
Experimental animals: 
            Species               : Wister albino Rats 
 Sex      : Male and Female  
 Age/weight at start of test  : 6 weeks/140-160g b.wt 
 Acclimatization Period  : 7 days prior to dosing 
Housing                                              :            Polypropylene cages with 
bedding with husk 
 Husbandry    : 12-h light/12-h dark artificial  
        photoperiod/ Room temperature 
        22°C(±3°) and relative humidity 
        30–70% 
 Feed and Water   :   Rodent pelleted feed   
                              RO purified water ad libitum 
Identification                               : Animals will be kept in   
Polypropylene cages and 
numbered  
 
Experimentation details   
             Groups/treatment regimen  :          Grouped by randomisation 
 Test guideline   :          WHO 
 Length of exposure to  
 test substance   :          90 days 
 No of animas   :        10 Female +10 Male / group 
 Control group   :          Vehicle 
 Test groups    :          Aagasagarudan kizhangu chooranam  
(Low, Mid, High dose) 
Albino rats of both sexes are divided into four groups. The first group treated 
as vehicle control and second, third, fourth group were treated with Aagasagarudan 
kizhangu chooranam i.e., Low dose, mid dose and high dose respectively. The control 
animals were administered with Water as a vehicle. The other animals were 
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administered with Aagasagarudan kizhangu chooranam orally for 90 days and it was 
monitored for behavioral parameters for the first 4 hours after drug administration 
every day. Body weight of the animal was monitored at weekly intervals. The food 
and water intake were calculated daily. The animals that die within this period will be 
subjected to necropsy. Remaining animals were weighed and sacrificed at the end of 
the study (91 days) by using the injection of Pentothal sodium. Blood was collected 
from the anesthetized animals from abdominal aorta. And the following investigations 
like Haematology, Biochemical analysis and Histopathology are done. 
 
 
Groups No. of Rats 
Group I:  Vehicle control (Water)    20(10M + 10F) 
Group II: Test drug - low dose (360mg/kg 
b.wt) 
20(10M + 10F) 
Group III: Test drug - Mid dose (720mg/kg 
b.wt) 
20(10M + 10F) 
GroupIV: Test drug - High dose (1.440mg/kg 
b.wt) 
20(10M + 10F) 
                                    Total:  80 (40 M + 40 F) 
                                               
Observations 
Experimental animals were kept under observation throughout the course of study for 
the following 
 
 Mortality, behavioural changes  
 All rats were observed twice daily  for  90 days 
 Body weight was observed once in a week. 
 Feed intake was calculated daily. 
 Water intake was calculated daily. 
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Cage-side observation 
The animals were monitored for behavioural parameters like Alertness, 
Mortality, convulsion, tremor, sedation, excitation, abnormal gait, motor 
coordination, piloerection, head movements, reactivity to touch, diarrhoea, 
salivation, lacrimation, posture, dyspnoea, coma. 
 
Laboratory investigation: 
On the 91th day, the animals were fasted overnight, then anesthetized to 
collect blood samples from the abdominal aorta in two tubes: one with EDTA for 
haematological parameters , another one without any anticoagulant and was 
centrifuged at 4000 rpm at 40C for 10 minutes to obtain the serum for biochemical 
parameters. 
 
Clinical Biochemistry 
At the end of the study, the animals were sacrificed, blood was collected in all 
the overnight fasted rats, through abdominal aorta .The blood sample was processed 
for the below mentioned investigations total cholesterol, triglycerides, Liver function 
test (SGOT, SGPT, alkaline phosphatase, total bilirubin, total protein, albumin, 
globulin), Renal function test (creatinine, urea). 
 
Haematological Investigation: 
Blood samples of control and experimental rats were analysed for 
Haemoglobin (Hb), Total red blood corpuscles (RBC), Total white blood corpuscles 
(WBC), Platelet, Mean corpuscular volume (MCV), Mean corpuscular haemoglobin 
(MCH) were calculated by auto analyser. 
 
Gross necropsy 
All the animals were sacrificed on the 91th day. Gross necropsy includes 
examination of the external surface of the body, all orifices, cranial, thoracic and 
abdominal cavities and their contents like Brain, eye, lung, heart, spleen, liver, kidney, 
testes and uterus of all animals were recorded.  
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Histopathology 
The organs included liver, kidneys, spleen, brain, heart, lungs, uterus, ovary, 
testes and stomach of the animals were preserved, and they were subjected to 
histopathological examination. 
Control and highest dose groups animals were initially subjected to 
histopathological investigation. If any abnormality found in the highest dose group 
then the low and mid dose group were also examined. Various organs (brain, heart, 
lung, liver, kidney, spleen, stomach)will be collected from all the animals and 
preserved in 10% buffered neutral formalin, sliced , 5 or 6μm sections and was stained 
with Haematoxylin and Eosin. Examined for histopathological changes. 
 
Statistical analysis: 
 Findings such as body weight changes, food consumption, water intake, 
haematology and biochemical analysis were subjected to One-way ANOVA Dunnet’s 
test using a computer software program followed by D Graph Pad Instat-3. 
 
RESULTS 
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5. RESULTS 
The prepared drug analyzed by various analytical procedures and studied by 
acute and long term toxicity studies through WHO guidelines. The results are given by 
the following tabulation, graphs and microscopical slides.  
 
5.1 QUALITATIVE ANALYTICAL STUDIES ON AAGASAGARUDAN KIZHANGU 
CHOORANAM 
1. Physico-chemical Analysis  
Table 1: Physico-chemical properties of Aagasagarudan kizhangu chooranam 
(AGC) 
S.No Parameters Percentage 
1. pH 6.5 
 2. Loss on drying  6.19% 
 3. Total Ash value  3.6% 
 4. Acid insoluble ash  0.4% 
 5. Water soluble ash  2.8% 
 6. Water soluble extraction  14.09% 
 7. Alcohol soluble extraction  11.69% 
 
RESULTS AND INTERPRETATION: 
  The pH level plays a role in enzyme activity by regulating the homeostasis. It 
is also an important factor for drug absorption. The pH of AGC is 6.5.  Being weak 
acidic,the drug is more readily absorbed in an acid medium like stomach which 
enhances the bioavailability of the drug. 
The moisture present in the drug was indicated in Loss on drying. The moisture 
content of the drug reveals the stability and its shelf-life.  Low moisture content could 
get maximum stability and better shelf life. Being a chooranam without incineration 
process the moisture content of AGC is 6.19%. So the stability and shelf life was 
about one year. 
The Total Ash value determines the amount of minerals and earthy materials present 
in the drug. The Ash value of AGC is 3.6% which denotes the purity of the drug as the 
ash value is low. 
 Acid insoluble ash value of the drug denotes the amount of siliceous matter 
(dust,sand etc.,)present in the drug.  
RESULTS 
 
PRECLINICAL SAFETY EVALUATION OF AAGASAGARUDAN KIZHANGU CHOORANAM  38 
 
 The quality of the drug is better if the acid insoluble Ash value is low. Here, 
acid insoluble ash value is 0.4%.hence it represents the superior quality of the AGC. 
Decreased Water soluble ash value(2.8 %) indicates easy facilitation of diffusion 
and osmosis mechanisms49.  
  
Table 2: Colour and Nature of Aagasagarudan kizhangu chooranam (AGC) 
 
S.No Parameters Results 
1. Colour Pale brown 
2. Odour  Pungent  
3. Taste  Bitter  
4. Texture  Fine powder 
5. Particle size  Completely passed through 
sieve no.88 
 
2. Biochemical Analysis  
Table 3: Biochemical analysis of Aagasagarudan kizhangu chooranam (AGC) 
S.No EXPERIMENT INFERENCE 
 1. Test for Silicate + 
 2. Test for Carbonate - 
 3. Test for Copper - 
 4. Test for Sodium - 
 5. Test for Sulphate - 
 6. Test for Chloride - 
 7. Test for Phosphate + 
 8. Test for Nitrate - 
 9. Test for Sulphide - 
 10. Test for Fluoride &Oxalate - 
 11. Test for Nitrite - 
RESULTS 
 
PRECLINICAL SAFETY EVALUATION OF AAGASAGARUDAN KIZHANGU CHOORANAM  39 
 
 12. Test for Lead - 
 13. Test for Aluminium - 
 14. Test for Iron + 
 15. Test for Zinc + 
 16. Test for Calcium + 
 17. Test for Magnesium - 
 18. Test for Ammonium + 
 19. Test for Potassium + 
 20. Test for Mercury - 
 21. Test for Arsenic - 
 22. Test for Starch + 
 23. Test for Reducing sugar - 
 24. Test for Alkaloids + 
 25. Test for Tannic acid - 
 26. Test for Amino acid - 
 27. Test for Phenol - 
             (+) Present (-) Absent 
 
RESULTS AND INTERPRETATION OF BIOCHEMICAL ANALYSIS 
The chemical analysis shows the presence of Silicate, Phosphate, Zinc, Iron, 
Calcium, Magnesium, Ammonium, Potassium, Starch, Alkaloids in Aagasagarudan 
kizhangu Chooranam. 
Phosphate is a charged particle that contains the mineral phosphorus.50. The 
mineral phosphorus is primarily used for growth and repair of body cells and 
tissues.51. It reduces the histamine release by activated mast cells52  
Zinc is deeply involved in regulation of immune system. Deficiency of zinc 
leads to development of inflammatory and autoimmune disorders53. So the presence of 
zinc in AGC cures the inflammatory disorders thereby regulating the immune system.  
 
 
RESULTS 
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5.2 QUANTITATIVE ANALYTICAL STUDIES ON AAGASAGARUDAN 
KIZHANGU CHOORANAM 
3. ICP-OES Analysis  
Table 4: Inductively Coupled Plasma Optical Emission Spectrometry Analysis of 
Aagasagarudan kizhangu Chooranam (AGC) 
 
Sl.No Element name Standard value Obtained value 
1 As 188.979 BDL 
2 Ca 315.807 24.150 mg/L 
3 Cd 228.802 BDL 
4 Cu 327.393 BDL 
5 Fe 238.204 2.340 mg/L 
6 Hg 253.652 BDL 
7 K 766.491 120.821 mg/L 
8 Mg 285.213 01.020 mg/L 
9 Na 589.592 13.110 mg/L 
10 Ni 231.604 BDL 
12 Pb 220.353 BDL 
13 P 213.617 58.541 mg/L 
14 Zn 213.856 01.587 mg/L 
               (BDL-Below Detection Limit) 
 
RESULTS AND INTERPRETATION OF ICP – OES ANALYSIS: 
The presence of some metals such as Calcium, Iron, Mercury, Potassium, 
Manganese, Sodium, Phosphorus and Zinc were detected in the sample of 
Aagasagarudan kizhangu chooranam. 
 The most important heavy metals such as lead, mercury, nickel, copper, arsenic and 
cadmium are present in BDL as per the WHO permissible levels in this purified 
sample. 
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4. GCMS Analysis 
Graphical representations - Gas Chromatogram Mass Spectrometer Analysis of 
Aagasagarudan kizhangu Chooranam (AGC) 
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Table 5: Gas Chromatogram Mass Spectrometer Analysis of 
Aagasagarudan kizhangu Chooranam (AGC)  
S.NO Rt Name of the compound Molecular 
formula 
Molecular 
weight 
(g/mol) 
1 18.43 9,12-Octadecadienoic acid, (2-
phenyl-1,3-dioxolan-4-yl)methyl 
ester, cis- 
 
C28H44O4 444.656 
2 16.17 Tridecanoic acid, methyl ester 
 
C14H28O2 228.376 
3 17.88 9, 12-Octadecadienoic acid, 
methyl ester 
 
C19H34O2 294.479 
4  19.34 Psi, psi carotene, 3,4 didehydro-1, 
2, 7’8’ – tetrahydro-1-methoxy-2-
oxo 
C41H58O2 582.913 
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5 20.62 1,1-Cyclobutanedicarboxamide, 
2-phenyl-N-N’-bis(1-
phenylethyl)- 
C28H30N2O2 426.56 
6 22.18 Cyclopentanepropanoic acid, 3,5 
bis(acetyloxy)-2-[-(acetyloxy)-3-
(methoxyimino)octyl]-, methyl 
ester 
  
 
 
RESULTS AND INTERPRETATION OF GCMS ANALYSIS: 
 
Through GCMS Analysis, the identified compounds in Aagasagarudan 
kizhangu chooranam are 9,12-Octadecadienoic acid, (2-phenyl-1,3-dioxolan-4-yl) 
methyl ester, cis-, Tridecanoic acid, methyl ester,9, 12-Octadecadienoic acid, methyl 
ester, Psi, psi carotene, 3,4didehydro-1, 2, 7’8’ –tetrahydro-1-methoxy-2-oxo, 1,1-
Cyclobutanedicarboxamide, 2-phenyl-N-N’-bis(1-phenylethyl)- 2-phenyl-N-N’-bis(1-
phenylethyl)-, Cyclopentanepropanoic acid, 3,5bis(acetyloxy)-2-[-(acetyloxy)-3-
(methoxyimino)octyl]-, methyl ester. These identified compounds like 9, 12-
Octadecadienoic acid, (2-phenyl-1,3-dioxolan-4-yl) methyl ester having so many 
medicinal values such as Hypocholesterolemic 5-Alpha reductase inhibitor, 
Antihistaminic, Anticoronary, Insectifuge, Hypocholesterolemic, Antieczemic, anti 
oxidant, anti microbial activity54. 
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5. FT-IR ANALYSIS 
Graphical representations - Fourtier Transform Infrared Spectroscopy Analysis 
of Aagasagarudan kizhangu Chooranam (AGC) 
 
AAGASAGARUDAN KIZHANGU CHOORANAM  
        
    Table 6: FTIR Analysis of Aagasagarudan kizhangu chooranam (AGC) 
Sl.no. Wavelength Vibrational modes Functional groups 
1 3509 -OH-Stretch-H-bonded  Alcohols, phenols 
2 3357 N-H stretch 1`, 2` amines, amides 
3 2162 -C≡C-stretch Alkynes 
4 1682 -C=C-stretch Alkenes 
5 1652 -C=C-stretch Alkenes 
6 1423 C-C stretch (in-ring) Aromatics 
7 1356 N-O symmetric stretch Nitro compound 
8 1252 C-O Stretch Alcohols, carboxylic acids, 
esters, ethers 
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9 1132 C-N Stretch Aliphatic amines 
10 1077 C-N Stretch Aliphatic amines 
11 1031 C-N Stretch Aliphatic amines 
12 999 = C-H Bend Alkenes 
13 947 O-H Bend Carboxylic acids 
14 831 C-Cl Stretch Alkyl halides 
15 706 -C≡C-H=C-H bend Alkynes 
16 540 C-Br stretch Alkyl halides 
 
RESULTS AND INTERPRETATION OF FT-IR ANALYSIS: 
In the FT-IR Spectra analysis, this Aagasagarudan kizhangu chooranam 
sample exhibits the peak value shows in Table 5 at the wave number of 3509, 3357, 
2162, 1682,1652, 1423, 1356, 1252, 1132,1077,1031,999,947,465,706,421,540,83. 
This indicates the presence of some organic functional groups such as alcohols, 
phenols,1`, 2` amines, amides, Alkynes, Alkenes, Alkyl halides, Nitro compound, 
Alcohols,  carboxylic acids, esters, ethers, Aliphatic amines, alkenes, Carboxylic 
acids, Aromatics. In this amide linkages in a biochemical context are called peptide 
bonds when they occur in the main chain of a protein and isopeptide bonds.  
Proteins can have structural roles such as in hair or spider silk, but also nearly all 
enzymes are proteins 55. 
The Aromatic compounds play key roles in the biochemistry of all living 
things. Aromatic amino acids serve as one of the 20 basic building blocks of proteins. 
The all 5 nucleotides make up the sequence of genetic code in DNA and RNA are 
aromatic purines or pyrimidines. The molecule heme contains an aromatic system 
with 22π electrons and chlorophyll also has a similar aromatic system. Amines and 
Carboxylic acids possess which enhances the drug effect against the disease. 
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5.3. TOXICOLOGICAL STUDIES ON AAGASAGARUDAN KIZHANGU 
CHOORANAM 
ACUTE TOXICITY STUDY OF AAGASAGARUDAN KIZHANGU 
CHOORANAM 
In Acute toxicity study carried out as per WHO guidelines, there were no 
treatment related death or signs of toxicity developed in Wister albino rats at 
therapeutic dose (2000mg/kg b.wt) throughout the study period. 
Further, no gross pathological changes have been seen in the internal organs of 
both control and treated groups. 
 
Table 7: Effect of Aagasagarudan kizhangu chooranam on Wister albino rats in 
Acute toxicity study 
 
S. 
No 
Dose mg/kg 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
 1 Control + - - + + + - - - - - - - - - - - - - - 
   
2 
Test Group 
therapeutic 
dose 
(2000mg/kg/b
.wt 
 
 
+ 
 
 
- 
 
 
- 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
1.Alertness 2.Aggressiveness 3.Pile erection 4.Grooming 5.Gripping 6.Touch 
response 7.Decreased Motor Activity 8.Tremors 9.Convulsion 10.Muscle spasm 
11.Catatonia 12.Muscle relaxant 13.Hypnosis 14.Analgesia 15.Lacrimation 
16.Exopthalmos 17.Diarrhoea 18.Writhing 19.Respiration 20.Mortality 
        
                  (+) Present (-) Absent 
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LONG TERM TOXICITY STUDY OF AAGASAGARUDAN KIZHANGU 
CHOORANAM 
Table 8: Effect of Aagasagarudan kizhangu chooranam on Body weight (gm) 
changes of Wister albino rats in Long term toxicity study 
GROUPS DAY1 15 30 45 60 75 90 
CONTROL 126± 
11.41 
153.6± 
53.60 
220± 
73.67 
233± 
73.04 
251± 
73.97 
270.3± 
82.10 
296.7± 
65.6 
LOW DOSE 123.6± 
21.5 
242.6± 
51.36** 
245± 
55.88 
266.1± 
63.93 
280.6± 
69.64 
290± 
71.28* 
293± 
73.28 
MID  
DOSE 
135.9± 
23.23 
248.1± 
41.93 
262.3± 
51.71 
278.2± 
54.68 
290.8± 
63.43 
312.4± 
61.81 
316.2± 
60.25 
HIGH 
DOSE 
138± 
22.98 
191.3± 
37.98 
254.3± 
52.63 
266± 
56.68 
279± 
59.16** 
289.5± 
64.81 
293.6± 
66.28 
 
Values are mean of 10 animals ± S.D.(Dunnett’s test). **(p <0.01),*(p < 0.05), n = 10. 
 
Graph 1: Effect of Aagasagarudan kizhangu chooranam on Body weight (gm) 
changes of Wister albino rats in Long term toxicity study 
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Table 9: Effect of Aagasagarudan kizhangu chooranam on food intake changes 
of Wister albino rats in Long term toxicity study 
GROUPS DAY1 15 30 45 60 75 90 
CONTROL 51.5± 
3.2 
64.5± 
3.53 
67± 
0.70 
66± 
2.82 
68.5± 
2.12 
69.5± 
0.70 
45± 
7.07 
LOW DOSE 46± 
21.2 
41± 
14.12 
51.5± 
12.02* 
52± 
22.62 
39.5± 
0.70 
49.5± 
0.70 
50± 
0.70 
MID 
 DOSE 
49± 
12.72 
45± 
21.2 
47± 
4.24 
41.5± 
4.94 
57.5± 
10.60 
60.5± 
3.53 
70± 
7.07 
HIGH DOSE 40± 
7.07 
42.5± 
10.60 
57.5± 
7.77 
62.5± 
7.77 
65± 
14.14 
74.5± 
21.92** 
68.5± 
2.12* 
 
Values are mean of 10 animals ± S.D.(Dunnett’s test). **(p <0.01),*(p < 0.05), n = 10. 
 
Graph 2: Effect of Aagasagarudan kizhangu chooranam on food intake (gm) 
changes of Wister albino rats in Long term toxicity study 
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WATER INTAKE: 
Table 10: Effect of Aagasagarudan kizhangu chooranam on Water intake 
changes of Wister albino rats in Long term toxicity study 
GROUPS DAY1 15 30 45 60 75 90 
CONTROL 90± 
14.14 
 
75± 
7.07 
 
70± 
14.14 
70± 
14.14 
65± 
7.07 
65± 
7.07 
57.5± 
10.60 
LOW DOSE 70± 
28.28 
60± 
28.28 
120± 
70.71* 
80± 
56.56 
90± 
42.42 
80± 
28.28 
85± 
7.07** 
MID 
DOSE 
95± 
63.63 
70± 
28.28 
100± 
42.42 
105± 
63.63 
95± 
7.07* 
120± 
84.85* 
90± 
28.28 
HIGH DOSE 100± 
42.42 
85± 
35.35 
110± 
28.28 
115± 
49.49 
85± 
21.21 
75± 
21.21 
110± 
14.14 
  
Values are mean of 10 animals ± S.D.(Dunnett’s test). **(p <0.01),*(p < 0.05), n = 10. 
 
Graph 3: Effect of Aagasagarudan kizhangu chooranam on Water intake 
changes of Wister albino rats in Long term toxicity study 
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Table 11: Effect of Aagasagarudan kizhangu chooranam on Hematological 
parameters of Wister albino rats in Long term toxicity study 
 
 
 
 
 
 
 
Parameter Control LD MD HD 
RBC (×106µl) 6.98±3.23 7.52±0.62 7.14±1.04* 6.78±1.24 
WBC(×103µl) 9.64±1.82 10.06±0.96* 9.58±2.98 9.59±1.36 
PLT(×103µl) 672.2±154.25 683.4±142.78 742±129.63 731.8±164.64 
HGB(g/dl) 13.52±1.44 13.46±2.88 13.86±1.95 14.14±0.95 
Neutrophils 
103mm3 
1.68±0.35 1.6±0.55 1.62±0.55 1.7±0.48 
 
Eosinophils (%) 1.27±0.31 1.48±0.24 1.26±0.004** 1.46±0.32 
Lymphocyte(%) 71.34±0.84 65.2±4.18 77.28±5.89 79.6±3.43 
Monocyte(%) 2.86±0.95 2.94±0.75 3.46±1.22 2.5±0.77 
Basophils (%) 0.1±0.58 0.2±0.45 0.1±0.31 0.1±0.31 
MCH(pg) 18.03±1.96 18.58±2.39 19.04±2.24 17.34±0.009** 
MCV (fl) 58.32±4.26 59.92±7.24 57.92±0.31 61.86±4.57 
 
     Values are mean of 10 animals ± S.D.(Dunnett’s test). **(p <0.01),*(p < 0.05), n = 10. 
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Graph 4: Effect of Aagasagarudan kizhangu chooranam on Hematological 
parameters – RBC of Wister albino rats in Long term toxicity study 
 
 
 
 
Graph 5: Effect of Aagasagarudan kizhangu chooranam on Hematological 
parameters – WBC of Wister albino rats in Long term toxicity study 
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Graph 6: Effect of Aagasagarudan kizhangu chooranam on Hematological 
parameters – Platelet count of Wister albino rats in Long term toxicity study 
 
 
 
 
Graph 7: Effect of Aagasagarudan kizhangu chooranam on Hematological 
parameters – Haemoglobin of Wister albino rats in Long term toxicity study 
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Graph 8: Effect of Aagasagarudan kizhangu chooranam on Hematological 
parameters – Differential count of Wister albino rats in Long term toxicity study 
 
 
 
 
Graph 9: Effect of Aagasagarudan kizhangu chooranam on Hematological 
parameters – MCH & MCV of Wister albino rats in Long term toxicity study 
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Table 12:  Effect of Aagasagarudan kizhangu chooranam on Biochemical 
parameters – Lipid profile of Wister albino rats in Long term toxicity study 
 
 
Dose(mg/kg) 
 
Control 
 
LD 
 
MD 
 
HD 
Total 
cholesterol 
(mg/dl) 
 
153.67±16.27 
 
145.32±23.81 
 
164.8±15.38 
 
153.04±7.36 
 
HDL (mg/dl) 
 
59.3±9.06 
 
56.3±6.04 
 
67.8±11.08 
 
61.6±0.04* 
 
LDL (mg/dl) 
 
76.47±11.81 
 
74.8±16.85 
 
81.6±12.88 
 
75.2±14.62 
 
VLDL (mg/dl) 
 
16.24±2.39 
 
17.81±4.68 
 
16.74±3.50 
 
16.81±4.19 
 
 
Triglycerides 
(mg/dl) 
 
33.53±4.06 
 
32.2±5.81 
 
33.4±0.14 
 
35.4±9.07 
 
 
Values are mean of 10 animals ± S.D.(Dunnett’s test). **(p <0.01),*(p < 0.05), n = 10. 
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Graph 10: Effect of Aagasagarudan kizhangu chooranam on Biochemical 
parameters – Lipid profile of Wister albino rats in Long term toxicity study 
 
 
 
 
Table 13:   Effect of Aagasagarudan kizhangu chooranam on Renal Parameters 
of Wister albino rats in Long term toxicity study 
 
Dose(mg/dl) Control LD MD HD 
BUN(mg/dl) 14.3±1.69 13.5±1.43 15.54±1.57 15.32±3.62 
Creatinine(mg/dl) 0.68±0.34 0.67±0.24 0.69±0.16 0.71±0.19 
 
Values are mean of 10 animals ± S.D.(Dunnett’s test). **(p <0.01),*(p < 0.05), n = 10. 
 
 
0
20
40
60
80
100
120
140
160
180
L
ip
id
 p
ro
fi
le
 i
n
 m
g
/d
l
EFFECT OF AAGASAGARUDAN KIZHANGU 
ON LIPID PROFILE
Control
Low dose
Mid dose
High dose
RESULTS 
 
PRECLINICAL SAFETY EVALUATION OF AAGASAGARUDAN KIZHANGU CHOORANAM  58 
 
Graph 11: Effect of Aagasagarudan kizhangu chooranam on Renal Parameters 
of Wister albino rats in Long term toxicity study 
 
 
 
 
Table 14:   Effect of Aagasagarudan kizhangu chooranam on Hepatic Parameters 
of Wister albino rats in Long term toxicity study 
 
Dose(mg/dl) Control LD MD HD 
Total Bilirubin 
(mg/dl) 
0.32±0.19 0.34±0.11 0.31±0.17 0.32±0.09 
SGOT(U/L) 115.6±32.21 126.6±28.97 113.6±24.08* 117.4±34.35 
SGPT(U/L) 33.45±3.54 34.4±4.62 31.2±5.81 34.2±9.13 
 
 
Values are mean of 10 animals ± S.D.(Dunnett’s test). **(p <0.01),*(p < 0.05), n = 10. 
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Graph 12:   Effect of Aagasagarudan kizhangu chooranam on Hepatic 
Parameters of Wister albino rats in Long term toxicity study 
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HISTOPATHOLOGICAL INVESTIGATION OF CONTROL AND 
AGC TREATED ANIMALS UNDER MAGNIFICATION POWER 
40X FOR 90 DAYS LONG TERM TOXICITY STUDY 
 
                                                      BRAIN 
Slide 1. CONTROL     Slide 2. HIGH DOSE 
   
 
BRAIN 
CONTROL: 
Arrangement of the neurons appears intact with no signs of degeneration or 
apoptotic changes in both the sample so cortex region showed normal neurons with 
polygonal to round cell bodies containing dense cytoplasm. 
 
HIGH DOSE: 
Appearance of Hippocampal neurons was normal with dense network o No 
signs of ischemic changes in the cerebral hemisphere 
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                                      HEART 
 
Slide 1. CONTROL        Slide 2. HIGH DOSE 
 
   
 
 
HEART 
CONTROL: 
Perfectly -arranged myocardial fibers, clear transverse striation and normal 
structure were observed. 
Appearance of cardiomyocyte was normal with dark nuclear region. The nuclei 
of muscle fibers appear oval arrangement 
 
HIGH DOSE: 
Myocardial cells appears normal with well-defined mycoplasma and 
prominent nucleus and nucleolus 
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                                                     LUNGS 
 
Slide 1. CONTROL     Slide 2. HIGH DOSE 
 
     
 
 
LUNGS: 
CONTROL: 
Bronchial opening appears regular with no signs of infiltration 
Appearance of alveolar network was normal 
Nucleus of type I and II alveolar cells looks normal 
HIGH DOSE: 
Perivascular region appears normal, Alveolar septa and wall appeared widen 
and normal 
No signs of lymphocyte cuffing 
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STOMACH 
          Slide 1. CONTROL        Slide 2. HIGH DOSE 
 
    
 
STOMACH: 
 
CONTROL: 
Gastric glands, gastric glands including secretary sheath appears normal 
Normal gastric mucosa containing intact gastric gland cells, parietal cells 
which are spherical cell with deeply stained dark nucleus 
 
HIGH DOSE: 
No signs of ulcer and glandular degeneration were observed 
Appearance of Sub-mucosa and gastric glands appear normal 
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                                              LIVER 
 
Slide 1. CONTROL    Slide 2. HIGH DOSE 
   
 
 
LIVER: 
 
CONTROL: 
Rare appearance of Kupffer cells with no evidence of phagocytosis in 
intracytoplasmic region 
Liver parenchyma appears normal with no evidence of necrosis 
Appearance of terminal hepatic venules (central veins) to the portal tracts was 
Normal 
 
HIGH DOSE: 
Apparent loss of liver parenchyma were observed 
Increase distant of liver sinusoids were observed 
Occasional presence of Kupffer cells with no evidence of phagocytosis in 
             intracytoplasmic region 
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                                                 KIDNEY 
 
Slide 1. CONTROL    Slide 2. HIGH DOSE 
 
    
 
 
KIDNEY: 
 
CONTROL: 
Appearance of Podocytes and parietal epithelium in the glomeruli appears 
normal 
Proximal and distal convoluted tubule appears normal 
No signs of lesion or inflammation were observed 
No signs of cellular necrosis 
 
HIGH DOSE: 
Some renal tubules appears hypertrophic 
Appearance of Podocytes and parietal epithelium in the glomeruli appears 
normal 
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                                               SPLEEN 
 
Slide 1. CONTROL    Slide 2. HIGH DOSE 
 
    
 
 
SPLEEN: 
 
CONTROL: 
No signs of perivascular inflammation 
Appearance of splenic sinuses, Splenic cord and endothelial orientation was 
normal 
Appearance of LF – lymphoid follicle; PALS – periarterial lymphoid sheath 
was normal with no significant signs of enlargement 
 
HIGH DOSE: 
Marginal vascular zone radiated in between red and white pulp 
Appearance of spleenic red pulp was normal 
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                                                  TESTES 
Slide 1. CONTROL    Slide 2. HIGH DOSE 
    
 
TESTES: 
 
CONTROL: 
Histocytology of testicular tissue shows well differentiated germ cells with 
respect of spermatogonia includes spermatid and sperm were observed 
Appearance of leydig cells, interstitial tissue, seminiferous tubule, Sertoli cells 
and spermatogonia were normal 
  
HIGH DOSE: 
Histo cytology of testicular tissue shows well differentiated germ cells with 
respect of spermatogonia includes spermatid and sperm were observed 
Appearance of leydig cells, interstitial tissue , seminiferous tubule, Sertoli cells 
And spermatogonia were normal 
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                                                 UTERUS 
 
Slide 1. CONTROL    Slide 2. HIGH DOSE 
    
 
UTERUS 
CONTROL: 
Appearance of endometrium,  
myometrium and  
uterine glands was normal.  
 
HIGH DOSE: 
Appearance of endometrium,  
myometrium and  
uterine glands was normal 
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OVARY 
 
Slide 1. CONTROL    Slide 2. HIGH DOSE 
    
 
OVARY 
CONTROL: 
Histopathological analysis of ovary showing normal corpus luteum (CL) and 
primordial follicles with few mature ovarian follicles with no signs of 
abnormality. 
 
HIGH DOSE: 
Appearance of antral follicle,  
primary oocyte and  
secondary follicles all were normal 
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6. DISCUSSION 
I have selected Aagasagarudan kizhangu chooranam to evaluate the safety 
profile. First with the test drug I have done the process of standardization with 
qualitative and quantitative analysis. The following are the analysis 
 Physico-chemical analysis 
  Biochemical Analysis 
  ICP-OES Analysis 
  GC-MS Analysis 
  FT-IR Analysis 
The safety profile is evaluated by Acute and Long Term toxicity studies on 
Wister Albino rats as per WHO guideline. 
            The Physico-chemical analysis of AGC (Table: 1) concludes the following 
results. The pH of AGC is 6.5.  Being weak acidic, the drug is more readily absorbed 
in an acid medium like stomach which enhances the bioavailability of the drug. 
 The loss on drying test is designed to measure the amount of water and volatile 
matters in a sample when the sample is dried under specified condition. Low moisture 
content is always desirable for higher stability of drugs. The percentage of loss on 
drying of AGC was 6.19% (Normal range: 1-20%). So Low moisture of AGC could 
get maximum stability and better shelf life.  
           The Ash limit Tests are designed to measure the amount of the residual. A high 
ash value is indicative of contamination, substitution, adulteration or carelessness in 
preparing the drug.The total Ash content and Acid Insoluble Ash values of AGC were 
3.6% (Normal range: 1-25%) and 0.4% (Normal range: 0.1 – 10%). This indicates the 
purity of the test drug.  
           Extraction value determines the amount of active constituents in a given 
amount of the formulation when extracted with a solvent media such as water and 
alcohol. The water soluble and alcohol soluble extract values provide an indication of 
the extent of polar and non polar compounds respectively present in AGC .The extract 
values of Alcohol in AGC is 11.69% and water is 14.09%. Decreased Water soluble 
ash value (2.8 %) indicates easy facilitation of diffusion and osmosis mechanisms.  
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 Biochemical Analysis of Aagasagarudan kizhangu chooranam for Acid 
radicals, Basic radicals, and other constituents demonstrates the presence of Silicate, 
Phosphate, Zinc, Iron, Calcium, Magnesium, Ammonium, Potassium, Starch and 
Alkaloids.  (Table3) 
        Phosphate is a charged particle that contains the mineral phosphorus. The 
mineral phosphorus is primarily used for growth and repair of body cells and tissues. 
It reduces the histamine release by activated mast cells. Zinc is deeply involved in 
regulation of immune system. Deficiency of zinc leads to development of 
inflammatory and autoimmune disorders. So the presence of zinc in AGC cures the 
inflammatory disorders thereby regulating the immune system.   
 The Quantitative Analysis of Aagasagarudan kizhangu chooranam 
through ICP-OES results showed that the Heavy metals like lead, mercury, nickel, 
copper, arsenic and cadmium were found in below detection level. Hence it may be 
safe for human consumption.  It also shows the presence of physiologically important 
minerals like Arsenic, Calcium, Cadmium, Copper, Iron, Mercury, Potassium, 
Manganese, Sodium, Nickel, Lead, Phosphorus and Zinc which are within ppm limit. 
(Table-4) 
      Through GCMS Analysis, the identified compounds in Aagasagarudan 
kizhangu chooranam are 9,12-Octadecadienoic acid, (2-phenyl-1,3-dioxolan-4-yl) 
methyl ester, cis-, Tridecanoic acid, methyl ester,9, 12-Octadecadienoic acid, methyl 
ester, Psi, psi carotene, 3,4didehydro-1, 2, 7’8’ –tetrahydro-1-methoxy-2-oxo, 1,1-
Cyclobutanedicarboxamide, 2-phenyl-N-N’-bis(1-phenylethyl)- 2-phenyl-N-N’-bis(1-
phenylethyl)-, Cyclopentanepropanoic acid, 3,5bis(acetyloxy)-2-[-(acetyloxy)-3-
(methoxyimino)octyl]-, methyl ester. These identified compounds like 9, 12-
Octadecadienoic acid, (2-phenyl-1,3-dioxolan-4-yl) methyl ester having so many 
medicinal values such as Hypocholesterolemic 5-Alpha reductase inhibitor, 
Antihistaminic, Anticoronary, Insectifuge, Hypocholesterolemic, Antieczemic, anti 
oxidant, anti microbial activity54.(Table 5) 
                    In the FT-IR Spectra analysis, this Aagasagarudan kizhangu chooranam 
sample exhibits the peak value indicates the presence of some organic functional 
groups such as alcohols, phenols,1`,2`amines, amides, Alkynes, Alkenes, Alkyl 
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halides, Nitro compound, Alcohols, carboxylic acids, esters, ethers, Aliphatic amines, 
alkenes, Carboxylic acids, Aromatics.   
           In this amide linkages in a biochemical context are called peptide bonds 
when they occur in the main chain of a protein and isopeptide bonds. Proteins can 
have structural roles such as in hair or spider silk, but also nearly all enzymes are 
proteins. The Aromatic compounds play key roles in the biochemistry of all living 
things. Aromatic amino acids serve as one of the 20 basic building blocks of proteins. 
The all 5 nucleotides make up the sequence of genetic code in DNA and RNA are 
aromatic purines or pyrimidines. The molecule heme contains an aromatic system 
with 22π electrons and chlorophyll also has a similar aromatic system. Amines and 
Carboxylic acids possess which enhances the drug effect against the disease 
          In Acute toxicity study there was no abnormal signs reported at the dose 
level of (2000 mg/kgb.wt) within 24hours in Wistar Albino Rats. No mortality and No 
pathological changes have been seen in the internal organs of both control and treated 
groups in the 14 days study period. And the Body weight, food intake and water intake 
of animals are normal. 
    Long term Toxicity Study was conducted for about 90 days as per WHO 
guideline in 3 doses Low dose (360mg/kg b.wt), Mid dose (720mg/kg b.wt), High 
dose (1440mg/kg b.wt). Animals were observed throughout the period. There was no 
significant change in body weight (Table: 8), food intake (Table: 9), and water intake 
(Table: 10). After 90 days animals were sacrificed and blood samples were collected 
and investigated. The results revealed that there were significant in RBC, WBC count 
and more significant changes in Eosinophils (Table 11). In hepatic parameter 
significant changes in SGOT (Table: 14) and in Biochemical parameter significant 
changes in HDL (Table: 12). The histopathological study on the organs such as brain, 
heart, lungs, kidney, spleen, liver, stomach, uterus, ovary and testes was normal in 
control, low dose, mid dose and high dose groups. 
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7. SUMMARY 
Aagasagarudan kizhangu chooranam was taken as dissertation drug for the 
evaluation of its toxicity profile. This is a single drug formulation which was prepared 
by purification of Aagasagarudan kizhangu through Pittaviyal process and 
administered with Naattu sarkkarai as adjuvant. The drug was chosen from the Siddha 
text Gunapadam mooligai vaguppu. The above drug is indicated for virulent poison, 
Anemia, Pruritus, Thyroidism, Leprosy and Herpes zoster. 
The raw drugs were procured from Rajan Herbals shop; Broadway, Chennai 
and the drugs were identified and authenticated by Asst.Professor of Botany, National 
Institute of Siddha. The drug was underwent physicochemical, biochemical analysis, 
heavy metal analysis using ICP-OES, Phytocompound analysis using GC-MS and 
organic functional group analysis using FT-IR techniques. Acute and long term 
toxicity studies were conducted as per WHO guideline.  
The weak acidic pH of AGC enhances the bioavailability of the drug. 
Decreased Water soluble ash value indicates easy facilitation of diffusion and osmosis 
mechanisms. 
The Ash value of the test drug shows the purity, 
ICP-OES results shows the heavy metals such as lead, mercury, nickel, copper, 
arsenic and cadmium were found in below detection level.  
The Biochemical analysis of the drug contains Silicate, Phosphate, Zinc, Iron, 
Calcium, Magnesium, Ammonium, Potassium, Starch and Alkaloids. 
Through GCMS analysis, the identified compounds like 9,12-Octadecadienoic 
acid, (2-phenyl-1,3-dioxolan-4-yl) methyl ester,  having so many medicinal values 
such as Hypocholesterolemic 5-Alpha reductase inhibitor, Antihistaminic, 
Anticoronary, Insectifuge, Hypocholesterolemic, Antieczemic, antioxidant and anti 
microbial activities.  
The FT-IR Spectra analysis indicates the presence of some organic functional 
groups such as alcohols, phenols,1`,2`amines, amides, Alkynes, Alkenes, Alkyl 
halides, Nitro compound, Alcohols, carboxylic acids, esters, ethers, Aliphatic amines, 
alkenes, Carboxylic acids, Aromatics. Amines and Carboxylic acids possess which 
enhances the drug effect against the disease. 
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The Acute toxicity study results revealed that no mortality in dose level 
2000mg/kg body weight group animals. It concludes that LD 50 cut-off of 
Aagasagarudan kizhangu chooranam may be above 2000mg//kg body weight as per 
WHO guideline. Long term toxicity study was conducted for about 90 days as per the 
WHO guideline. The different dose levels of Aagasagarudan kizhangu chooranam 
selected were Low dose (360mg/kg b.wt), Mid dose (720mg/kg b.wt) and High dose 
(1440mg/kg b.wt) respectively. The control animals were administered normal saline 
only. 
The haematology and biochemical parameters were subjected to one way 
ANOVA analysis which shows no significant changes in CBC, Lipid profile, RFT and 
LFT in all test groups compared to control group in blood. The histopathology report 
of organs reveals that all organs  such as Brain, Heart, Lung, Stomach, Liver, spleen, 
kidney, testes, uterus and ovary  were normal in low, mid and high dose groups when 
compared to control group. 
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8. CONCLUSION 
From the results of this study, the qualitative analysis of (AGC) reveals the 
Purity and Bioavailability of the drug. As heavy metals were found in Aagasagarudan 
kizhangu chooranam are within the permissible limit, the drug is safe enough for oral 
consumption. Toxicity studies states that there was no mortality and signs of toxicity 
observed for acute oral administration of AGC with the therapeutic dose (2000 mg/kg 
b.wt) in the prescribed manner. In long term toxicity study there was no significant 
changes in haematological, biochemical parameter in AGC treated groups when 
compared to control group. The histopathology report also confirms that there are no 
remarkable cellular changes at all the dose levels. It clearly demonstrates that there 
was No Observed Adverse Effect Level (NOAEL) upto the high dose level (1440 
mg/kg b.wt). Based on these results it can be conclude that, the dose level of 
Aagasagarudan kizhangu chooranam 2 to 4gm (Arai muthal oru varaagan alavu) 
mentioned in the Siddha literature Gunapadam mooligai vaguppu is safe dosage for 
human consumption. 
In upcoming days it should be carried out to study the pharmacological activity 
and clinical trial to prove the efficacy of the drug. 
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